Updated clinical guidelines on Effient treatment for ACS patients

Effient® (prasugrel) tablets, a new antiplatelet medicine, was added as a treatment option in two clinical guideline updates: one for patients receiving percutaneous coronary intervention (PCI) and a second one for patients with ST elevation myocardial infarction (STEMI), or severe heart attack. The two 2009 focused updates for the clinical guidelines, jointly developed by the American Heart Association (AHA), the American College of Cardiology (ACC), and the Society for Cardiovascular Angiography and Interventions (SCAI), were published online today in Circulation, the Journal of the American College of Cardiology and Catheterization and Cardiovascular Interventions.

Approved by the U.S. Food and Drug Administration in July 2009, Effient is indicated to lower the chance of having another thrombotic cardiovascular event such as heart attack or stent-related blood clot for patients with acute coronary syndromes (ACS) who are managed with angioplasty and stenting, also known as PCI.

Effient received the Class I recommendation from the Guidelines Committee in both sets of the guideline updates. Class I means that a given "procedure/treatment should be performed/administered" to patients, given it was found to be "useful/ effective/beneficial". Consistent with the Effient label, both guidelines provide recommendations to avoid the use of Effient in patients with a prior history of TIA or stroke.

"It is important that the cardiology community has updated clinical guidelines that include the latest treatment options like Effient for treating ACS patients managed with angioplasty and stenting," said LeRoy LeNarz, M.D., senior medical director of cardiovascular care, Lilly USA, LLC. "By recommending Effient, these guidelines recognize an important new treatment for ACS-PCI patients, particularly for those with severe heart attacks who are at increased risk of suffering future cardiovascular events."

"The Guidelines Committee classified prasugrel, marketed in the United States as Effient, with a Class I rating," said Rogelio Braceras, M.D., senior medical director for Daiichi Sankyo, Inc. "Based on the latest clinical studies and scientific evidence, these guidelines provide clear recommendations for how Effient should be incorporated into medical practice to help reduce risk of cardiovascular events such as heart attacks and blood clots forming around stents."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
SpaceX CRS-31 supports heart health, neurodegeneration, and student science